Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/chd.12760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial.
Heart
January 2025
Health Economics Unit, School of Health Sciences, University of Birmingham, Birmingham, UK
Background: Atrial fibrillation (AF) is a major and increasing burden on health services. This study aimed to evaluate the cost-effectiveness of digoxin versus beta-blockers for heart rate control in patients with permanent AF and symptoms of heart failure.
Methods: RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) was a randomised, open-label, blinded, endpoint trial embedded in the UK National Health Service (NHS) to directly compare low-dose digoxin with beta-blockers (ClinicalTrials.
Herb-drug interaction potential of : a metabolic perspective.
Drug Metab Rev
December 2024
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
(AR) is one of the most widely used herbs in Asia and has a wide range of biological activities. These activities are attributed to its various compounds like flavonoids, saponins, and polysaccharides. AR and its major components are often used in combination with other drugs for the treatment of diseases such as cancer and cerebral ischemia.
View Article and Find Full Text PDFAntiarrhythmic preferences and outcomes post DC cardioversion for atrial fibrillation, an Australian rural perspective.
Aust J Rural Health
August 2024
Department of Cardiology, Dubbo Base Hospital, Dubbo, New South Wales, Australia.
Introduction: Direct current cardioversion (DCCV) remains one of the recommended management strategies for symptomatic atrial fibrillation (AF). Antiarrhythmic drugs (AAD) are prescribed post procedure to maintain sinus rhythm (SR). Limited literature exists on the AAD prescribing practices and their efficacy, post-DCCV in rural Australia.
View Article and Find Full Text PDFA Comprehensive Review on Unveiling the Journey of Digoxin: Past, Present, and Future Perspectives.
Cureus
March 2024
Pediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Digoxin, a cardiac glycoside derived from the foxglove plant ( spp.), has been utilized for centuries in managing various cardiac conditions due to its ability to increase myocardial contractility and regulate heart rate. This comprehensive review explores the historical context, pharmacological properties, clinical applications, efficacy, safety profile, challenges, and future perspectives of digoxin.
View Article and Find Full Text PDFChemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.
J Med Life
April 2023
Dr. Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq.
Cancer is a major public health problem, and chemotherapy plays a significant role in the management of neoplastic diseases. However, chemotherapy-induced cardiotoxicity is a serious side effect secondary to cardiac damage caused by antineoplastic's direct and indirect toxicity. Currently, there are no reliable and approved methods for preventing or treating chemotherapy-induced cardiotoxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!